Testolone is a promising new anabolic drug that inhibits growth of AR/ER+ breast cancer cells by reducing the gene ESR1. Its tissue-selective AR activity and its oral availability make it a promising candidate to conduct clinical research in patients. It is crucial to remember that professional athletes are not permitted to take this drug which … Read more

RAD 140, a promising new anabolic drug, blocks the growth of breast cancer AR/ER+ cells by suppressing ESR1. Its tissue-selective AR activity, oral availability, and general tolerance in animal models make it an attractive candidate for clinical investigation for patients. However, before evaluating its use, it is crucial to keep in mind that this drug … Read more

RAD 140, a promising new anabolic medication, inhibits the growth of AR/ER+ breast carcinoma cells by suppressing ESR1. Its tissue-specific AR activity and oral accessibility, as well as general acceptance in animal models makes it an attractive candidate for clinical studies for patients. But, before considering its use, it’s important to know that this substance … Read more

RAD 140, a promising new anabolic drug, inhibits the growth of AR/ER+ breast carcinoma cells by reducing ESR1. Its tissue-specific AR activity and oral accessibility make it a promising candidate for clinical research on patients. However, prior to considering its use, it is important to note that this substance is not approved for use by … Read more

Testolone is a promising new anabolic agent that blocks growth of AR/ER+ breast cancer cells by suppressing the gene ESR1. Its tissue-specific AR activity as well as its oral availability and overall safety in animal models make it an attractive possibility for clinical study for patients. However, before considering its use, it’s important to know … Read more

RAD 140, a promising new anabolic medication, inhibits the growth of AR/ER+ breast carcinoma cells by reducing ESR1. Its tissue-selective AR activity and oral accessibility make it a promising candidate to conduct clinical research in patients. It is important to remember that professional athletes aren’t allowed to use this drug, so it should be avoided. … Read more

RAD 140, a promising new anabolic medication, inhibits the growth of AR/ER+ breast carcinoma cells by suppressing ESR1. Its tissue-specific AR activity and its oral availability makes it a viable candidate for clinical research on patients. But, before considering its use, it is crucial to be aware that this substance is not approved for use … Read more

Testolone is a promising new anabolic compound that inhibits the growth of breast cancer AR/ER+ cells by reducing the gene ESR1. Its tissue-specific AR activity and its oral availability make it a promising candidate for clinical research with patients. It is crucial to remember that professional athletes are not allowed to use this drug, so … Read more

RAD 140, a promising new anabolic drugthat blocks the growth of AR/ER+ breast cancer cells by suppressing ESR1. Its tissue-selective AR activity, oral availability, and general acceptance in animal models makes it a promising possibility for clinical study for patients. However, prior to considering its use, it is crucial to be aware that this substance … Read more

RAD 140, a promising new anabolic drug, blocks the growth of AR/ER+ breast cancer cells by reducing ESR1. Its tissue-specific AR activity and its oral availability make it a potential candidate to conduct clinical research in patients. But, before considering its use, it’s important to know that this substance is not approved for use by … Read more